The use of leukotriene receptor antagonists (LTRAs) as complementary therapy in asthma

Monaldi Archives for Chest Disease - Pulmonary Series

Volumn 57, Issue 1, 2002, Pages 76-83

  Bjermer, Leif ^a   Diamant, Z ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Additive therapy; Anti inflammatory effects; Asthma; Leukotriene receptor antagonists

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE PHOSPHATE; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID DERIVATIVE; FLUTICASONE PROPIONATE; FORMOTEROL; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEUKOTRIENE SYNTHESIS INHIBITOR; LONG ACTING DRUG; MONTELUKAST; PEPTIDOLEUKOTRIENE; PLACEBO; PRANLUKAST; PREDNISONE; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; STEROID; UNCLASSIFIED DRUG; ZAFIRLUKAST; ZILEUTON;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG CHOICE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DYSPHONIA; EOSINOPHIL; EXERCISE INDUCED ASTHMA; EXHALATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LUNG FUNCTION; NIGHT; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PROTECTION; PROVOCATION TEST; REVIEW; SYMPTOM; URINE;

EID: 14244271223     PISSN: 11220643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Asthma: A disease of inflammation and repair
2. Mucosal inflammation in asthma
3. Functional significance of increased airway smooth muscle in asthma and COPD
4. Airway hyperresponsiveness, inflammation, and subepithelial collagen deposition in recently diagnosed versus long-standing mild asthma. Influence of inhaled corticosteroids
5. Clinical control and histopathological outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group
6. Mucosal inflammation in severe glucocorticoid-dependent asthma
7. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroids
8. Effect of inhaled formeterol and budesonide on exacerbations of asthma
9. 2-agonist salmeterol xinafoate: Effects on airway inflammation in asthma
10. The effect of salmeterol on markers of airway inflammation following segmental allergen challenge
11. The effects of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma
12. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells
13. An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma
14. Potential masking effects of salmeterol on airway inflammation in asthma
15. Anti-inflammatory mechanisms of leukotriene modulators
16. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects
17. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: Bronchoalveolar lavage fluid findings after segmental antigen challenge
18. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings
19. Leukotriene-receptor antagonists
20. Urinary excretion of inflammatory mediators during allergen-induced early and late phase asthmatic reactions
21. Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion
22. Bone marrow events in animal models of allergic inflammation and hyperresponsiveness
23. Effect of oral prednisone on airway inflammatory mediators in atopic asthma
24. Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells
25. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group
26. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids
27. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients
28. Use of montelukast in tapering inhaled corticosteroid therapy: An open-label, 48-week trial
29. Montelukast for chronic asthma in 6- to 14-year-old children: A randomized, double-blind trial. Pediatric Montelukast Study Group
30. Montelukast added to budesonide in children with persistent asthma: A randomized, double-blind, crossover study
31. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroids
32. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids
33. Effect of inhaled formeterol and budesonide on exacerbations of asthma
34. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma
35. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group
36. Improved lung function and rapid control achieved with the new single inhaler product containing both budesonide and formoterol in asthmatic children aged 4-17 years
37. Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature
38. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics
39. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma
40. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics
41. Improvement of aspirin-intolerance asthma by montelukast a leukotriene antagonist: A randomized, double-blind placebo-controlled trial
42. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy
43. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast
44. The bronchoconstrictor activity of adenosine in asthma
45. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids
46. Oral montelukast compared to inhaled salmeterol in adult asthmatics with exercise induced asthma (EIA) receiving inhaled fluticasone
47. Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma
48. 4 in the assessment of nocturnal asthma
49. Nocturnal asthma is associated with reduced glucocorticoid receptor binding affinity and decreased steroid responsiveness at night
50. Inflammatory cell distribution within and along asthmatic airways
51. History and future perspectives of treating asthma as a systemic and small airways disease
52. Nordic consensus report on asthma management. Nordic Asthma Consensus Group
53. Montelukast or salmeterol combined with an inhaled steroid in adult asthma (the IMPACT - Investigation of Montelukast as a Partner Agent for Complementary Therapy - Trial)